EU funds are leaning in. The German press is covering the round. US investors take the meeting, ask about the technology, and pass. The narrative the US deeptech investor scans for is not on slide one. It is not on the deck.
PASS.
If the US investor wants a CTO meeting and not a customer call, the technology already passed. The market evidence layer is what is failing.
EU deeptech investing has historically rewarded technical depth, founding-team credentials, IP position, and the early scientific validation that the technology works. The deck reflects this. Slide one is the technology. Slide two is the founding team and the lab provenance. Slide three is the patent stack. Customers and revenue appear later. This works in Munich. Munich-area investors read in this order.
US deeptech investing has shifted toward a market-first scoring model. The technology has to work, but that is a precondition. The round thesis is built on named US design partners or paid pilots, a quantified US ARR or revenue line however modest, a stated US TAM with bottom-up build to a US category, US peer comparable inside the round dynamics, and a US-based founder or operating presence. Without these, the US investor reads the company as a research project that has not validated the commercial path.
Per Roland Berger deeptech outlook and IMAP venture & growth equity report, US deeptech rounds in 2025 and 2026 have explicitly tightened on named US design partners and US ARR for any company outside pure research-frontier categories. White & Case M&A Explorer 2026 shows European deeptech exits trending toward later-stage US acquirers, who in turn read the same signals the US investor scoring uses.
The Munich firm typically has the technology and is missing the market evidence layer. The fix is not to dilute the technology story. The fix is to lead with market evidence and place technology depth in support. 5 US market signals on the first three slides, with the technology depth available on demand for the technical-deep-dive meeting.
If you opened your deck with a named US design partner, a US ARR figure however modest, and a US-built bottom-up TAM, what would slide one of your current deck have to lose to make room?
"EU investors fund the technology. US investors fund the market. The Munich firm with great tech still has to build the second deck."House reading on deeptech capital narrative
Stage one: build the named US market evidence. Convert one or two European pilots into named US design partners with paid pilot status, even at small scale. Where US ARR exists, restate it in US-investor format with retention, contract length, and named customer. Where US ARR is in pipeline, structure the next 90 days to convert one US deal into citable form. Build a bottom-up US TAM to a named US category with traceable assembly.
Stage two: resequence the deck. Slide one names the US design partner, the US ARR figure however modest, and the US TAM. Slide two is the market problem with named US comparables. Slide three is the named US peer set inside the round dynamics. Technology depth moves to slide five or six. Founding team and IP move to the appendix or the technical-deep-dive deck. The first three slides carry the market evidence the US investor scores on.
Stage three: stage the US presence. A US-based founder hire, a US operating lead, or a US advisory bench with named US deeptech veterans creates the fifth scan signal. The hire does not have to be in San Francisco. It has to be visible, named, and operating inside US deeptech conversation. The next US investor meeting hears a different story.
This work fits inside a Market Entry Sprint (six to ten weeks, one fundraise, one US category), a Cross-Border Build (three to six months, full US investor and commercial rebuild), or a Group Partnership (monthly retainer, twelve-month minimum, for deeptech groups with multiple US-facing programmes). Pricing is confirmed in discovery, not on the public site.
| Before rebuild (EU deeptech narrative) | After rebuild (US deeptech narrative) |
|---|---|
| Slide one: technology architecture and IP position | Slide one: named US design partner, US ARR, US TAM |
| TAM: top-down global figure | TAM: bottom-up build to a named US category with adjacencies |
| Customer evidence: European pilots | Customer evidence: named US design partners with paid pilot status |
| Founding team: European labs and credentials | Founding team + US operating presence with named US advisors |
| US investor outcome: polite pass after technical meeting | US investor outcome: term sheet conversation inside two cycles |
| Round shape: EU-only | Round shape: blended EU-US with US lead in play |
Market evidence first, deck second, US presence third. Technology depth is a precondition. It is not the round thesis.
"US deeptech investor scoring has tightened on first-read market evidence over the last three years. Named US design partners and bottom-up US TAM construction now carry more weight than headline technology claims for deeptech firms outside pure research-frontier categories."
"We were testing demand and got polite signals back. The hardest part wasn't the build, it was figuring out which signal was real and which was just everyone being friendly because we were the new firm in the room."
EU deeptech investors weight technology depth, founding team credentials, and patent strength as load-bearing on first read. US deeptech investors weight market evidence on first read: named US design partners, US-paid pilots, quantified US ARR or revenue line, US peer comparables, and a stated US TAM with bottom-up build. The Munich deck typically opens technology-first and arrives in the US investor's inbox without the market evidence the US reader scans for. The technology is interesting and the file fails on market signal.
Five things: a named US design partner or paid pilot, a quantified US ARR or revenue line however modest, a stated US TAM with bottom-up build to a US category, a US peer comparable inside the round dynamics, and a US-based founder or operating presence. None of these are about the technology itself. All of them are about market evidence. The US deeptech investor accepts that the technology works as a precondition, not as the round thesis.
A US founder or US operating presence helps with the fifth scan signal. It does not substitute for the first four. A Munich deeptech firm with a US-based founder and no US design partners and no US ARR still fails on the market evidence layer. The hire is a complement to the rebuild, not the rebuild.
Often. Munich deeptech firms typically present a top-down TAM derived from global market sizing. US investors want a bottom-up build to a named US category with named adjacent comparables. A bottom-up US TAM smaller than the top-down global TAM is read as more credible than a large headline number with no traceable assembly. Per Roland Berger deeptech outlook, US deeptech investors explicitly weight bottom-up TAM construction over headline figures.
Inquiry through the contact form and a discovery conversation. Send the current US-facing investor deck, the last three US investor passes with feedback if available, the US TAM material, and the US design-partner or pilot pipeline. Response within one business day. Pricing confirmed in discovery, not on the public site.
No legal services. No US entity formation. No fundraising placement agency function. No SEC, FINRA, or any other regulator registration. No US tax structuring, double-tax-treaty analysis, or transfer pricing. No US banking introductions. No fiduciary services. No IP filing or patent prosecution. No technology development, applied R&D, or scientific consulting. No M&A advisory. No executive search or hiring. The legal, fundraising, technical, and operational substance sits with counsel, placement agents, technical advisors, and operational consultants on both sides of the corridor. The firm rebuilds the US-facing investor narrative and the commercial surface that runs alongside it. When a marketing decision touches legal, fundraising, regulatory, or technical implications, the firm flags it and defers before execution.